<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-04-29T00:41:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9336066" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9336066</identifier>
        <datestamp>2022-07-30</datestamp>
        <setSpec>bmcorhl</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Oral Health</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Oral Health</journal-id>
              <journal-title-group>
                <journal-title>BMC Oral Health</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1472-6831</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9336066</article-id>
              <article-id pub-id-type="pmcid">PMC9336066</article-id>
              <article-id pub-id-type="pmc-uid">9336066</article-id>
              <article-id pub-id-type="pmid">35906582</article-id>
              <article-id pub-id-type="publisher-id">2348</article-id>
              <article-id pub-id-type="doi">10.1186/s12903-022-02348-2</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A prospective interventional study of recombinant human interleukin-11 mouthwash in chemotherapy-induced oral mucositis</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2904-7086</contrib-id>
                  <name>
                    <surname>Wei</surname>
                    <given-names>Hangping</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wei</surname>
                    <given-names>Juan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Dong</surname>
                    <given-names>Xiaofang</given-names>
                  </name>
                  <address>
                    <email>dongxiaofang2022@163.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>Department of Medical Oncology, </institution><institution>Affiliated Dongyang Hospital of Wenzhou Medical University, </institution></institution-wrap>No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People’s Republic of China </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>22</volume>
              <elocation-id>313</elocation-id>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">This prospective interventional study aimed to evaluate and analyse the efficacy of rhIL-11 mouthwash compared to Kangfuxin fluid in treatment and blank control in prevention of oral mucositis (OM) in patients receiving chemotherapy.</p>
                </sec>
                <sec>
                  <title>Materials and Methods</title>
                  <p id="Par2">In total, 50 patients in the treatment group and 62 patients in the prevention group were included. Subsequently, each group was divided into an experimental group and a control group. In the treatment group, the experimental patients received recombinant human interleukin-11 (rhIL-11) mouthwash, whereas the control group received Kangfuxin fluid. In the prevention group, experimental patients still received rhIL-11 mouthwash based on routine oral care, whereas the control group only received routine oral care. Meanwhile, we observed and recorded the efficacy in the treatment group, and the occurrence and grades of OM in the prevention group.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Through statistical analysis, the results showed that on the seventh day of treatment, the experimental group showed more improvement compared to the control group, and it was statistically significant (<italic>p</italic> = 0.032). The average healing time in the experimental group (3.59 ± 1.927 days) was shorter than that in the control group (4.96 ± 2.421 days; <italic>p</italic> = 0.031). In the prevention group, we observed the incidence of oral mucositis. No significant differences were found in the occurrence and grades of OM in the experimental and control groups (<italic>p</italic> = 0.175).</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">Our preliminary results indicate that rhIL-11 mouthwash may be a superior option to treat OM, especially in severe cases, compared to Kangfuxin fluid. However, there is no advantage in prevention.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Oral mucositis</kwd>
                <kwd>Recombinant human interleukin-11</kwd>
                <kwd>Chemotherapy</kwd>
                <kwd>Treatment</kwd>
                <kwd>Prevention</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004731</institution-id>
                      <institution>Natural Science Foundation of Zhejiang Province</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>LGF19H160003</award-id>
                  <award-id>LGF19H160003</award-id>
                  <award-id>LGF19H160003</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Wei</surname>
                      <given-names>Hangping</given-names>
                    </name>
                    <name>
                      <surname>Wei</surname>
                      <given-names>Juan</given-names>
                    </name>
                    <name>
                      <surname>Dong</surname>
                      <given-names>Xiaofang</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par8">Oral mucositis (OM) is a frequent complication of cancer treatment toxicities, occurring in approximately 20–60% of cancer patients receiving conventional antineoplastic therapies [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. Previous research demonstrates that the pathophysiology of OM is a complex, multistage phenomenon that can result from oral mucosal cell damage caused by free radicals produced by chemotherapy drugs [<xref ref-type="bibr" rid="CR4">4</xref>]. It involves amplified inflammatory responses, reduced cell proliferation, increased cell senescence/apoptosis, and impaired regenerative potential in both the mucosal and submucosal compartments [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].Lesions may be erosive or ulcerative and can cause mild to severe pain. Although the condition is self-limiting, it usually leads to a significant decrease in the quality of life due to prolonged hospital stay, altered nutritional status, increased risk of infection, and increased prescription of opioids. Moreover, it has a negative impact on the delivery of optimal cancer treatments [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. For these reasons, it is extremely necessary to treat OM, with the goal of preventing or reducing the severity of lesions and managing the associated symptoms, thereby allowing the continuation of cancer therapy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].
</p>
              <p id="Par9">Recently, a growing number of OM remedies has been suggested in the literature, including basic oral care, antimicrobial agents, anaesthetics and analgesics, laser therapy, and oral cryotherapy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Basic oral care is considered the backbone of supportive care for patients receiving cancer treatment, which could reduce the incidence of moderate to severe OM [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. At present, mixed medication mouthwashes, which include antibacterial drugs, analgesics, vitamin B12, Xilei powder and hormone therapy, are widely used clinically [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
              <p id="Par10">The glycoprotein recombinant human interleukin-11 (rhIL-11) is a pleiotropic cytokine that exhibits diverse therapeutic effects [<xref ref-type="bibr" rid="CR11">11</xref>]. It has been widely used for treating bone marrow suppression caused by chemotherapy and radiotherapy since its discovery in a mouse lung-conditioned medium in 1977 [<xref ref-type="bibr" rid="CR12">12</xref>]. Recent studies have found that rhIL-11 can directly promote the proliferation and migration of endothelial cells, enhance the activity of other angiogenic factors, and promote healing of the mucosa [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Currently, there are a few articles focusing on the value of rhIL-11 in OM, and there is no strong evidence that rhIL-11 can be recommended for the prevention and treatment of OM.</p>
              <p id="Par11">Therefore, we predict that rhIL-11, combined with normal saline, can directly act on oral epithelial cells when used as an oral wash and promote the healing of OM by accelerating the proliferation of oral epithelial cells. The purpose of this research is to prospectively evaluate whether rhIL-11 is more effective, compared to Kangfuxin fluid in treatment and blank control in prevention of oral mucositis (OM) in patients receiving chemotherapy.</p>
            </sec>
            <sec id="Sec2">
              <title>Materials and methods</title>
              <sec id="Sec3">
                <title>Patients</title>
                <p id="Par12">This prospective interventional study was a randomized control trial conducted from January 2019 to March 2022 on patients receiving chemotherapy in the Department of Oncology at Affiliated Dongyang Hospital of Wenzhou Medical University. Patients older than 18 years; those receiving non-systemic medication; those with previous head and neck radiotherapy time of less than 1 year; those with allergies, oral lesions, or serious illnesses (transaminase more than twice the normal value, renal failure, and infection, among others); or an Eastern Cooperative Oncology Group performance status score of &gt; 2 were excluded. Those who failed to gargle as directed were also excluded. The study rationale was explained to the trial participants, and written informed consent was obtained prior to enrolment. Finally, 50 patients in the treatment group and 62 patients in the prevention group completed the study and were analysed.</p>
              </sec>
              <sec id="Sec4">
                <title>Study design</title>
                <p id="Par13">Patients who would receive a systemic chemotherapy were assigned to the prevention group (n = 62) and were selected using a random distribution into the experimental group (n = 34) and control group (n = 28). A random number table was used for random distribution. Patients in the experimental group received rhIL-11 mouthwash (3 mg lyophilised powder of rhIL-11, which was dissolved in distilled water and added to 100 mL normal saline) based on routine oral care (brushing teeth, gargling, and daily oral hygiene monitoring) during chemotherapy, whereas the control group only received routine oral care. Patients were instructed to gargle 10 mL of solution four times per day (morning, lunch, after dinner, and before going to bed) for 2–3 min each time.</p>
                <p id="Par14">Patients with OM of degree II or above after the current round of chemotherapy were assigned to the treatment group (n = 50) and were selected using a random distribution into the experimental (n = 27) and control groups (n = 23). A random number table was also used for random distribution. Patients in the experimental group received rhIL-11 mouthwash (3 mg lyophilised powder of rhIL-11, which was dissolved in distilled water and added to 100 mL normal saline) compared to Kangfuxin fluid (its main chemical component is <italic>Periplaneta americana</italic> extract, a liquid drug that can significantly promote angiogenesis and growth of granulation tissue, accelerate the shedding of necrotic tissue, and rapidly repair ulcers and wounds; it has been used widely used in clinic and has been shown the effect in the treatment of oral mucositis [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]) in the control group in those patients with OM after chemotherapy. Instructions for the two mouthwashes were the same as those for the prevention group. The ulcer was also smeared with a cotton ball, and treatment continued until the ulcer healed. Local treatment helps to accelerate the healing of oral mucositis.</p>
              </sec>
              <sec id="Sec5">
                <title>Evaluation</title>
                <p id="Par15">The scale proposed by the World Health Organization classifies OM in five degrees: Grade 0, incipient and asymptomatic lesions; Grade I, slight oral soreness and erythema; Grade II, oral erythema, small ulcers, solid diet tolerated; Grade III, large oral ulcers, liquid diet only; Grade IV, severe ulcers, bleeding, pain, and oral alimentation impossible. On this scale, Grades III and IV correspond to severe OM. Oral mucositis healing refers to OM of degree 0, that is, the elimination of ulcers and reduction of pain.</p>
                <p id="Par16">Every morning before administration, medication record, curative effect observation, and effect evaluation were made by specialised staff (a trained nurse blinded to the intervention), and the injury site, ulcer area size, ulcer number, and pain degree were evaluated according to the OM grading standards. The treatment group was followed up to the basic healing of oral mucositis, and the preventive group was followed up to the beginning of the next cycle of chemotherapy.</p>
              </sec>
              <sec id="Sec6">
                <title>Ethics approval and consent to participate</title>
                <p id="Par17">The study has been approved by the ethics committee of our hospital.</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical analysis</title>
                <p id="Par18">The clinical data were described using medians, frequencies, and percentages. SPSS 22.0 software was used for statistical analysis. The measurement data were analysed using the T-test, and counting data were analysed using the chi-square test or wilcoxon test. A <italic>p</italic> value of &lt; 0.05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec id="Sec8">
              <title>Results</title>
              <sec id="Sec9">
                <title>Efficacy of rhIL-11 in the treatment group</title>
                <sec id="Sec10">
                  <title>Patient demographics and baseline characteristics</title>
                  <p id="Par19">In the experimental and control groups, the ratio of males to females was 1.17:1, and the median age was 63.6 years (range, 26–81 years). The patients included were mostly undergoing treatment for thoracic and abdominal tumours, such as lung and intestinal cancer. The majority comprised stage IV patients who had received chemotherapy previously. There was no significant difference in general characteristics among the groups (<italic>p</italic> &gt; 0.05) (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics in the treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left">Experimental group</th><th align="left">Control group</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">n (%)</th><th align="left">n (%)</th></tr></thead><tbody><tr><td align="left" colspan="3">Age</td><td align="left" rowspan="3"><italic>p</italic> = 0.643</td></tr><tr><td align="left"> ≥ 65 years</td><td char="(" align="char">17(63)</td><td char="(" align="char">13(56.5)</td></tr><tr><td align="left"> &lt; 65 years</td><td char="(" align="char">10(37)</td><td char="(" align="char">10(43.5)</td></tr><tr><td align="left" colspan="3">Gender</td><td align="left" rowspan="3"><italic>p</italic> = 0.811</td></tr><tr><td align="left"> Male</td><td char="(" align="char">15(55.6)</td><td char="(" align="char">12(52.2)</td></tr><tr><td align="left"> Female</td><td char="(" align="char">12(44.4)</td><td char="(" align="char">11(47.8)</td></tr><tr><td align="left" colspan="3">Tumour site</td><td align="left" rowspan="5"><italic>p</italic> = 0.817</td></tr><tr><td align="left"> Head and neck</td><td char="(" align="char">3(11.1)</td><td char="(" align="char">2(8.7)</td></tr><tr><td align="left"> Chest</td><td char="(" align="char">10(37.0)</td><td char="(" align="char">10(43.5)</td></tr><tr><td align="left"> Abdomen</td><td char="(" align="char">11(40.7)</td><td char="(" align="char">10(43.5)</td></tr><tr><td align="left"> Other</td><td char="(" align="char">3(11.1)</td><td char="(" align="char">1(4.3)</td></tr><tr><td align="left" colspan="3">Disease stage</td><td align="left" rowspan="4"><italic>p</italic> = 0.167</td></tr><tr><td align="left"> II</td><td char="(" align="char">1(3.7)</td><td char="(" align="char">0(0)</td></tr><tr><td align="left"> III</td><td char="(" align="char">7(25.9)</td><td char="(" align="char">2(8.7)</td></tr><tr><td align="left"> IV</td><td char="(" align="char">19(70.4)</td><td char="(" align="char">21(91.3)</td></tr><tr><td align="left" colspan="3">PS</td><td align="left" rowspan="4"><italic>p</italic> = 0.403</td></tr><tr><td align="left"> 0</td><td char="(" align="char">0(0)</td><td char="(" align="char">1(4.3)</td></tr><tr><td align="left"> 1</td><td char="(" align="char">20(74.1)</td><td char="(" align="char">14(60.9)</td></tr><tr><td align="left"> 2</td><td char="(" align="char">7(25.9)</td><td char="(" align="char">8(34.8)</td></tr><tr><td align="left" colspan="3">Chemotherapeutic drugs</td><td align="left" rowspan="6"><italic>p</italic> = 0.475</td></tr><tr><td align="left"> Platinum ± 5-FU</td><td char="(" align="char">9(33.3)</td><td char="(" align="char">5(21.7)</td></tr><tr><td align="left"> Paclitaxel</td><td char="(" align="char">8(29.6)</td><td char="(" align="char">11(47.8)</td></tr><tr><td align="left"> EN Huan</td><td char="(" align="char">2(7.4)</td><td char="(" align="char">2(8.7)</td></tr><tr><td align="left"> Target</td><td char="(" align="char">6(22.2)</td><td char="(" align="char">2(8.7)</td></tr><tr><td align="left"> Other</td><td char="(" align="char">2(7.4)</td><td char="(" align="char">3(13)</td></tr><tr><td align="left" colspan="3">Previous chemotherapy</td><td align="left" rowspan="3"><italic>p</italic> = 0.114</td></tr><tr><td align="left"> Yes</td><td char="(" align="char">20(74.1)</td><td char="(" align="char">21(91.3)</td></tr><tr><td align="left"> No</td><td char="(" align="char">7(25.9)</td><td char="(" align="char">2(8.7)</td></tr><tr><td align="left" colspan="3">Previous radiotherapy</td><td align="left" rowspan="3"><italic>p</italic> = 0.857</td></tr><tr><td align="left"> Yes</td><td char="(" align="char">4(14.8)</td><td char="(" align="char">3(13)</td></tr><tr><td align="left"> No</td><td char="(" align="char">23(85.2)</td><td char="(" align="char">20(87)</td></tr></tbody></table></table-wrap></p>
                </sec>
                <sec id="Sec11">
                  <title>Comparison of the efficacy of experimental and control groups</title>
                  <p id="Par20">OM in this study was predominantly classified as stage II, accounting for 76% of all cases, and the severity of OM before treatment in the two groups was not statistically significant (<italic>p</italic> = 0.696) (Table <xref rid="Tab2" ref-type="table">2</xref>). On the second and fourth days of treatment, there was no significant improvement in the two groups. (<italic>p</italic>  = 0.793, 0.069) (Table <xref rid="Tab2" ref-type="table">2</xref>). However, on the seventh day of treatment, the experimental group showed more improvement compared to the control group, and it was statistically significant (<italic>p</italic> = 0.032) (Table <xref rid="Tab2" ref-type="table">2</xref>). The average healing time was 3.59 ± 1.927 days in the experimental group and 4.96 ± 2.421 days in the control group (<italic>p</italic> = 0.031) (Table <xref rid="Tab3" ref-type="table">3</xref>). As a result, among all the treatment patients, the efficacy was higher in the experimental group than in the control group. The average healing time of the experimental group was shorter than that of the control group.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Oral mucositis in the experimental and control groups on the second, fourth, and seventh day of treatment within the treatment group (the wilcoxon test was adopted)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Classification of oral mucositis</th><th align="left" colspan="2">Before treatment</th><th align="left" colspan="2">D2</th><th align="left" colspan="2">D4</th><th align="left" colspan="2">D7</th></tr><tr><th align="left">Experimental group (n)</th><th align="left">Control group (n)</th><th align="left">Experimental group (n)</th><th align="left">Control group (n)</th><th align="left">Experimental group (n)</th><th align="left">Control group (n)</th><th align="left">Experimental group (n)</th><th align="left">Control group (n)</th></tr></thead><tbody><tr><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">2</td><td align="left">0</td><td align="left">15</td><td align="left">7</td><td align="left">24</td><td align="left">15</td></tr><tr><td align="left">I</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">4</td><td align="left">8</td><td align="left">10</td><td align="left">3</td><td align="left">4</td></tr><tr><td align="left">II</td><td align="left">21</td><td align="left">17</td><td align="left">19</td><td align="left">13</td><td align="left">3</td><td align="left">2</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left">III</td><td align="left">4</td><td align="left">3</td><td align="left">5</td><td align="left">5</td><td align="left">1</td><td align="left">4</td><td align="left">0</td><td align="left">3</td></tr><tr><td align="left">IV</td><td align="left">2</td><td align="left">3</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">P value</td><td align="left" colspan="2"><italic>p</italic> = 0.696</td><td align="left" colspan="2"><italic>p</italic> = 0.793</td><td align="left" colspan="2"><italic>p</italic> = 0.069</td><td align="left" colspan="2"><italic>p</italic> = 0.032</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Healing rate of the experimental and control groups within the treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment</th><th align="left">No. of patients</th><th align="left">Healing time (days)</th><th align="left">T value</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Experimental group</td><td align="left">27</td><td char="." align="char">3.59 ± 1.927</td><td align="left" rowspan="2">2.218</td><td align="left" rowspan="2">0.031</td></tr><tr><td align="left">Control group</td><td align="left">23</td><td char="." align="char">4.96 ± 2.421</td></tr></tbody></table></table-wrap></p>
                </sec>
              </sec>
              <sec id="Sec12">
                <title>Efficacy of rhIL-11 in the prevention group</title>
                <sec id="Sec13">
                  <title>Patient demographics and baseline characteristics</title>
                  <p id="Par21">The ratio of males to females was 1.21:1, and the median age was 62.6 years. Most of them (98.3%) were thoracic or abdominal tumors and were in the advanced stage of the disease. There was no difference in gender, age, disease location, chemotherapeutic drugs and disease condition between the two groups (Table <xref rid="Tab4" ref-type="table">4</xref>, <italic>p</italic> &gt; 0.05).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Patient characteristics in the prevention group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left">Experimental group</th><th align="left">Control group</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">n (%)</th><th align="left">n (%)</th></tr></thead><tbody><tr><td align="left" colspan="3">Age</td><td align="left" rowspan="3"><italic>p</italic> = 0.368</td></tr><tr><td align="left"> ≥ 65 years</td><td char="(" align="char">16(47.1)</td><td char="(" align="char">10(35.7)</td></tr><tr><td align="left"> &lt; 65 years</td><td char="(" align="char">18(52.9)</td><td char="(" align="char">18(64.3)</td></tr><tr><td align="left" colspan="3">Gender</td><td align="left" rowspan="3"><italic>p</italic> = 0.368</td></tr><tr><td align="left"> Male</td><td char="(" align="char">16(47.1)</td><td char="(" align="char">10(35.7)</td></tr><tr><td align="left"> Female</td><td char="(" align="char">18(52.9)</td><td char="(" align="char">18(64.3)</td></tr><tr><td align="left" colspan="3">Tumour site</td><td align="left" rowspan="5"><italic>p</italic> = 0.311</td></tr><tr><td align="left"> Head and neck</td><td char="(" align="char">0(0)</td><td char="(" align="char">1(3.6)</td></tr><tr><td align="left"> Chest</td><td char="(" align="char">15(44.1)</td><td char="(" align="char">17(60.7)</td></tr><tr><td align="left"> Abdomen</td><td char="(" align="char">18(52.9)</td><td char="(" align="char">9(32.1)</td></tr><tr><td align="left"> Other</td><td char="(" align="char">1(2.9)</td><td char="(" align="char">1(3.6)</td></tr><tr><td align="left" colspan="3">PS</td><td align="left" rowspan="4"><italic>p</italic> = 0.990</td></tr><tr><td align="left"> 0</td><td char="(" align="char">4(11.8)</td><td char="(" align="char">3(10.7)</td></tr><tr><td align="left"> 1</td><td char="(" align="char">7(20.6)</td><td char="(" align="char">6(21.4)</td></tr><tr><td align="left"> 2</td><td char="(" align="char">23(67.6)</td><td char="(" align="char">19(67.9)</td></tr><tr><td align="left" colspan="3">Chemotherapeutic drugs</td><td align="left" rowspan="6"><italic>p</italic> = 0.857</td></tr><tr><td align="left"> Platinum ± 5-FU</td><td char="(" align="char">15(44.1)</td><td char="(" align="char">16(57.1)</td></tr><tr><td align="left"> Paclitaxel</td><td char="(" align="char">10(29.4)</td><td char="(" align="char">7(25)</td></tr><tr><td align="left"> EN Huan</td><td char="(" align="char">1(2.9)</td><td char="(" align="char">1(3.6)</td></tr><tr><td align="left"> Target</td><td char="(" align="char">6(17.6)</td><td char="(" align="char">3(10.7)</td></tr><tr><td align="left"> Other</td><td char="(" align="char">2(5.9)</td><td char="(" align="char">1(3.6)</td></tr></tbody></table></table-wrap></p>
                </sec>
                <sec id="Sec14">
                  <title>Comparison of the experimental and control groups in the prevention group</title>
                  <p id="Par22">The OM incidence rates were 11.8% and 25% in the experimental and control groups, respectively (Chi square test was used according to the incidence of OM, <italic>p</italic> = 0.175). In order to further analyse the severity of oral mucositis, the wilcoxon test was used (<italic>p</italic> = 0.16 Table <xref rid="Tab5" ref-type="table">5</xref>). As a result, the occurrence and grades of OM in the experimental and control group showed no significant differences.<table-wrap id="Tab5"><label>Table 5</label><caption><p>OM incidence rate in the experimental and control groups within the prevention group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Prevention</th><th align="left" rowspan="2">No. of patients</th><th align="left" colspan="5">Classification of oral mucositis</th><th align="left" rowspan="2">Incidence rate</th></tr><tr><th align="left">0</th><th align="left">I</th><th align="left">II</th><th align="left">III</th><th align="left">IV</th></tr></thead><tbody><tr><td align="left">Experimental group</td><td align="left">34</td><td align="left">30(88.2%)</td><td align="left">3(8.8%)</td><td align="left">1(3%)</td><td align="left">0(0%)</td><td align="left">0(0%)</td><td char="." align="char">11.8%</td></tr><tr><td align="left">Control group</td><td align="left">28</td><td align="left">21(75%)</td><td align="left">4(14.3%)</td><td align="left">2(7.1%)</td><td align="left">1(3.6%)</td><td align="left">0(0%)</td><td char="." align="char">25.0%</td></tr><tr><td align="left">P value</td><td align="left"/><td align="left" colspan="5"><italic>p</italic> = 0.16 (the wilcoxon test was adopted)</td><td align="left"><italic>p</italic> = 0.175</td></tr></tbody></table></table-wrap></p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec15">
              <title>Discussion</title>
              <p id="Par23">OM is a common adverse effect of anticancer therapy, typically occurring within 1 week of undergoing chemotherapy. In addition to causing discomfort and pain, OM may affect the quality of life of cancer patients by prolonging hospitalisation and increasing financial expenses. Therefore, it is increasingly important to understand the mechanisms of OM lesions to provide effective prevention and treatment. Clinically, different chemotherapy regimens can cause different degrees of OM. Current research indicates that antimetabolites, which affect DNA synthesis, are associated with 40–60% of OM incidences, with the use of 5-FU and platinum derivatives (cisplatin and oxaliplatin) resulting in more severe OM [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. Although no evidence for a cumulative effect with repeated chemotherapy cycles has been found, considering the use of the same drugs and the sensitivity of the body, it remains necessary to consider using prophylactic drugs for patients with a history of severe OM [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
              <p id="Par24">Prevention and treatment of OM is necessary to relieve symptoms, accelerate tissue repair, and promote successful chemotherapy. Many treatments, including basic oral care, antimicrobial agents, and natural medicine using substances such as honey, aim to reduce both the incidence and severity of OM [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. However, these treatments have their own limitations, including cariogenic effects and adherence to teeth following prolonged ingestion of honey [<xref ref-type="bibr" rid="CR24">24</xref>]. Previous studies suggest that preventive oral spray can delay the occurrence of OM [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Some studies showed that laser therapy and cryotherapy reduced the incidence of severe oral mucositis and reduced pain [<xref ref-type="bibr" rid="CR14">14</xref>]. Though much research has been done on the role of cytokines (mostly GM-CSF and G-CSF) in oral mucositis, results have been inconsistent [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref>].</p>
              <p id="Par25">RhIL-11 is a pleiotropic cytokine which stimulates myeloid, erythroid, and megakaryocyte differentiation, modulates macrophage and T cell inflammatory functions, and protects the function of the mucosal epithelium [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. It is also known to promote mitosis and proliferation by inhibiting apoptosis and improving the mitotic activity of small intestinal villi stem progenitor cells, and it has a good protective effect on gastrointestinal tract injuries caused by radiotherapy and chemotherapy. The oral mucosa is similar to the intestinal mucosa in terms of continuous self-renewal and rapid proliferation [<xref ref-type="bibr" rid="CR28">28</xref>]. Thus, rhIL-11 has the potential to reduce chemotherapy-related OM. Moreover, epithelial cells contain the colony-stimulating factor receptor, which is bound by rhIL-11 to stimulate the migration and proliferation of epithelial cells and promote the growth of keratinocytes and fibroblasts [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, rhIL-11 may promote the proliferation and maturation of endothelial cells to accelerate the healing of OM caused by chemotherapy.</p>
              <p id="Par26">Our data were collected prospectively, eliminating potential recall bias and increasing credibility compared to a retrospective design. Prior research in an animal model found that rhIL-11 favourably modulates acute radiation-induced mucositis by attenuating pro-inflammatory cytokine expression [<xref ref-type="bibr" rid="CR29">29</xref>]. Unfortunately, there is no relevant prospective research to support these findings. In the present study, the results showed that rhIL‐11 therapy significantly reduced the recovery time of OM (3.59 ± 1.927 days vs. 4.96 ± 2.421 days; <italic>p</italic> = 0.031) and improved the efficiency of treatments compared with Kangfuxin fluid, supporting the ability of rhIL‐11 to accelerate recovery from OM. In addition, this study demonstrates there was no significant difference in the efficacy of rhIL-11 or Kangfuxin fluid in the first few days, but after 1 week of treatment, the efficacy of rhIL-11 in OM was better than Kangfuxin fluid. This further indicates that rhIL-11 may shorten the treatment time of severe OM. This study also found that no advantage of rhIL-11 treatment in preventing OM, both the incidence and degree of oral mucositis. At present, many studies have shown that low-intensity laser therapy, honey and probiotics play a role in prevention.</p>
              <p id="Par27">However, there are few a samples after radiotherapy in this study. According to previous studies, the incidence of OM related to radiotherapy of head and neck tumours is high and the treatment time is long, which need to be further investigated. Moreover, the severity of chemotherapy-induced OM in this study is low, which may offset the results. In addition, the main limitation of our experiment is the small sample size of this study; therefore, further high‐quality, large‐scale studies are needed to verify our conclusions.</p>
            </sec>
            <sec id="Sec16">
              <title>Conclusions</title>
              <p id="Par28">In summary, our preliminary results indicate that recombinant human interleukin-11 mouthwash may be a superior option option to treat OM, especially in severe cases, compared to Kangfuxin fluid. Considering the cost of rhIL-11, recombinant human interleukin-11 mouthwash is not recommended for preventing OM in patients receiving chemotherapy.
</p>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>OM</term>
                  <def>
                    <p id="Par5">Oral mucositis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>rhIL-11</term>
                  <def>
                    <p id="Par6">Recombinant human interleukin-11</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PS</term>
                  <def>
                    <p id="Par7">Performance status</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors would like to acknowledge the following people, who have made the completion of the present study possible: department colleagues, such as Yifang Lu and Xiaoyan Hu, for their assistance, and the patients, for their support.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>DXF and WHP were responsible for conceiving and designing the study. WHP and WJ carried out the acquisition and analysis of the data. WHP drafted the manuscript. WHP and WJ revised and edited the manuscript. All authors contributed signifcantly, read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This study was supported by a grant from the natural science foundation of Zhejiang Province (LGF19H160003).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>All data generated or analysed during this study are included in this published article. And the primary data could be achieved from the corresponding author.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par29">The authors declare no competing interests.</p>
              </notes>
              <notes id="FPar2">
                <title>Ethics approval and consent to participate</title>
                <p id="Par30">All the stages of the research were carried out under the Declaration of Helsinki. All participants volunteered for the study, were informed of its scope, provided written consent. This research protocol was approved by Dongyang Hospital Affiliated to Wenzhou Medical University institutional research committee, registration number: 2019-YX-011). All participants signed aninformed consent form before data gathering.</p>
              </notes>
              <notes id="FPar3">
                <title>Consent for publication</title>
                <p id="Par31">Not applicable.</p>
              </notes>
              <notes id="FPar4" notes-type="COI-statement">
                <title>Conflicting interests</title>
                <p id="Par32">The authors declare no potential conflicts of interest with respect to the research, authorship, and publication of this article.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Le</surname>
                      <given-names>AD</given-names>
                    </name>
                  </person-group>
                  <article-title>Oral mucositis: an update on innate immunity and new interventional targets</article-title>
                  <source>J Dent Res</source>
                  <year>2020</year>
                  <volume>99</volume>
                  <issue>10</issue>
                  <fpage>1122</fpage>
                  <lpage>1130</lpage>
                  <pub-id pub-id-type="doi">10.1177/0022034520925421</pub-id>
                  <?supplied-pmid 32479139?>
                  <pub-id pub-id-type="pmid">32479139</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hong</surname>
                      <given-names>BY</given-names>
                    </name>
                    <name>
                      <surname>Sobue</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Choquette</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dupuy</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Burleson</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis</article-title>
                  <source>Microbiome</source>
                  <year>2019</year>
                  <volume>7</volume>
                  <issue>1</issue>
                  <fpage>66</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40168-019-0679-5</pub-id>
                  <?supplied-pmid 31018870?>
                  <pub-id pub-id-type="pmid">31018870</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Potten</surname>
                      <given-names>CS</given-names>
                    </name>
                  </person-group>
                  <article-title>Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine surviral time</article-title>
                  <source>Stem Cell</source>
                  <year>1996</year>
                  <volume>14</volume>
                  <issue>4</issue>
                  <fpage>452</fpage>
                  <lpage>459</lpage>
                  <pub-id pub-id-type="doi">10.1002/stem.140452</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sonis</surname>
                      <given-names>ST</given-names>
                    </name>
                    <name>
                      <surname>Peterson</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Edwards</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Lucey</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Mason</surname>
                      <given-names>WL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters</article-title>
                  <source>Oral Oncol</source>
                  <year>2000</year>
                  <volume>36</volume>
                  <issue>4</issue>
                  <fpage>373</fpage>
                  <lpage>381</lpage>
                  <pub-id pub-id-type="doi">10.1016/s1368-8375(00)00012-9</pub-id>
                  <?supplied-pmid 10899677?>
                  <pub-id pub-id-type="pmid">10899677</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cinausero</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Aprile</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ermacora</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Basile</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Vitale</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Fanotto</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>New frontiers in the pathobiology and treatmentof cancer regimen-related mucosal injury</article-title>
                  <source>Front Pharmacol</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <issue>8</issue>
                  <fpage>354</fpage>
                  <pub-id pub-id-type="doi">10.3389/fphar.2017.00354</pub-id>
                  <pub-id pub-id-type="pmid">28642709</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maria</surname>
                      <given-names>OM</given-names>
                    </name>
                    <name>
                      <surname>Eliopoulos</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Muanza</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Radiation-induced oral mucositis</article-title>
                  <source>Front Oncol</source>
                  <year>2017</year>
                  <volume>22</volume>
                  <issue>7</issue>
                  <fpage>89</fpage>
                  <pub-id pub-id-type="doi">10.3389/fonc.2017.00089</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>López-González</surname>
                      <given-names>Á</given-names>
                    </name>
                    <name>
                      <surname>García-Quintanilla</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Guerrero-Agenjo</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Tendero</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Guisado-Requena</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Rabanales-Sotos</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Eficacy of cryotherapy in the prevention of oral mucosistis in adult patients with chemotherapy</article-title>
                  <source>Int J Environ Res Public Health</source>
                  <year>2021</year>
                  <volume>18</volume>
                  <issue>3</issue>
                  <fpage>994</fpage>
                  <pub-id pub-id-type="doi">10.3390/ijerph18030994</pub-id>
                  <?supplied-pmid 33498628?>
                  <pub-id pub-id-type="pmid">33498628</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>YT</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>XR</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>ZZ</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>XH</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of 9 oral care solutions on the prevention of oral mucositis: a network meta-analysis of randomized controlled trials</article-title>
                  <source>Medicine</source>
                  <year>2020</year>
                  <volume>99</volume>
                  <issue>16</issue>
                  <fpage>e19661</fpage>
                  <pub-id pub-id-type="doi">10.1097/MD.0000000000019661</pub-id>
                  <?supplied-pmid 32311938?>
                  <pub-id pub-id-type="pmid">32311938</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kusiak</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jereczek-Fossa</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Cichońska</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Alterio</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Oncological-therapy related oral mucositis as an interdisciplinary problem—literature review</article-title>
                  <source>Int J Environ Res Public Health</source>
                  <year>2020</year>
                  <volume>17</volume>
                  <issue>7</issue>
                  <fpage>2464</fpage>
                  <pub-id pub-id-type="doi">10.3390/ijerph17072464</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mubaraki</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pani</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Alseraihy</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Abed</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Alkhayal</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>The efficacy of two different oral hygiene regimens on the incidence and severity of oral mucositis in pediatric patients receiving hematopoietic stem cell transplantation: a prospective interventional study</article-title>
                  <source>Spec Care Dentist</source>
                  <year>2020</year>
                  <volume>40</volume>
                  <issue>6</issue>
                  <fpage>566</fpage>
                  <lpage>573</lpage>
                  <pub-id pub-id-type="doi">10.1111/scd.12525</pub-id>
                  <?supplied-pmid 32964512?>
                  <pub-id pub-id-type="pmid">32964512</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dai</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Teng</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multicenter, randomized study of genetically modified recombinant Human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy</article-title>
                  <source>Support Care Cancer</source>
                  <year>2012</year>
                  <volume>20</volume>
                  <issue>8</issue>
                  <fpage>1875</fpage>
                  <lpage>1884</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-011-1290-x</pub-id>
                  <?supplied-pmid 22041866?>
                  <pub-id pub-id-type="pmid">22041866</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Yan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of recombinant human interleukin-11 in thetreatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: a systematic review and meta-analysis</article-title>
                  <source>J Eval Clin Pract</source>
                  <year>2020</year>
                  <volume>26</volume>
                  <issue>1</issue>
                  <fpage>262</fpage>
                  <lpage>271</lpage>
                  <pub-id pub-id-type="doi">10.1111/jep.13152</pub-id>
                  <?supplied-pmid 31222870?>
                  <pub-id pub-id-type="pmid">31222870</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Antin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Neuberg</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Alyea</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Soiffer</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Sonis</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation</article-title>
                  <source>Bone Marrow Transplant</source>
                  <year>2002</year>
                  <volume>29</volume>
                  <issue>5</issue>
                  <fpage>373</fpage>
                  <lpage>377</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.bmt.1703394</pub-id>
                  <?supplied-pmid 11919725?>
                  <pub-id pub-id-type="pmid">11919725</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daugėlaitė</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Užkuraitytė</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Jagelavičienė</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Filipauskas</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis</article-title>
                  <source>Medicina</source>
                  <year>2019</year>
                  <volume>55</volume>
                  <issue>2</issue>
                  <fpage>25</fpage>
                  <pub-id pub-id-type="doi">10.3390/medicina55020025</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tian</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dong</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Shuliang</surname>
                      <given-names>Lu</given-names>
                    </name>
                    <name>
                      <surname>Geng</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>The effects and mechanism of Kangfuxin on improving healing quality and preventing recurrence of gastric ulcer</article-title>
                  <source>Biomed Pharmacother</source>
                  <year>2021</year>
                  <volume>138</volume>
                  <fpage>111513</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111513</pub-id>
                  <?supplied-pmid 33761454?>
                  <pub-id pub-id-type="pmid">33761454</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wei</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Jie</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Meng</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A Bioadhesive barrier-forming oral liquid gel improved oral mucositis and nutritional status in patients with head and neck cancers undergoing radiotherapy: a retrospective single center study</article-title>
                  <source>Front Oncol</source>
                  <year>2021</year>
                  <volume>22</volume>
                  <issue>11</issue>
                  <fpage>617392</fpage>
                  <pub-id pub-id-type="doi">10.3389/fonc.2021.617392</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Dou</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of four types of watermelon frost combination medications for the treatment of oral ulcers: a network meta-analysis</article-title>
                  <source>J Healthc Eng</source>
                  <year>2022</year>
                  <volume>2022</volume>
                  <fpage>2712403</fpage>
                  <pub-id pub-id-type="doi">10.1155/2022/2712403</pub-id>
                  <?supplied-pmid 35313513?>
                  <pub-id pub-id-type="pmid">35313513</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bano</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Najam</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Qazi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mateen</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX</article-title>
                  <source>Asian Pac J Cancer Prev</source>
                  <year>2014</year>
                  <volume>15</volume>
                  <issue>19</issue>
                  <fpage>8089</fpage>
                  <lpage>8093</lpage>
                  <pub-id pub-id-type="doi">10.7314/apjcp</pub-id>
                  <?supplied-pmid 25338989?>
                  <pub-id pub-id-type="pmid">25338989</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chibaudel</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Lacave</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lefevre</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Soussan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Antoine</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Périé</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study</article-title>
                  <source>Cancer Med</source>
                  <year>2015</year>
                  <volume>4</volume>
                  <issue>5</issue>
                  <fpage>721</fpage>
                  <lpage>731</lpage>
                  <pub-id pub-id-type="doi">10.1002/cam4.408</pub-id>
                  <?supplied-pmid 25684313?>
                  <pub-id pub-id-type="pmid">25684313</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Curra</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Soares Junior</surname>
                      <given-names>LAV</given-names>
                    </name>
                    <name>
                      <surname>Martins</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Santos</surname>
                      <given-names>PS</given-names>
                    </name>
                  </person-group>
                  <article-title>Chemotherapy protocols and incidence of oral mucositis. An integrative review</article-title>
                  <source>Einstein</source>
                  <year>2018</year>
                  <volume>16</volume>
                  <issue>1</issue>
                  <fpage>eRW4007</fpage>
                  <pub-id pub-id-type="doi">10.1590/s1679-45082018rw4007</pub-id>
                  <?supplied-pmid 29694618?>
                  <pub-id pub-id-type="pmid">29694618</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leng</surname>
                      <given-names>SX</given-names>
                    </name>
                    <name>
                      <surname>Elias</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Interleukin-11</article-title>
                  <source>Int J Biochem Cell Biol</source>
                  <year>1994</year>
                  <volume>15</volume>
                  <issue>1–2</issue>
                  <fpage>45</fpage>
                  <lpage>49</lpage>
                  <pub-id pub-id-type="doi">10.3109/10428199409051676</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boerma</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Burnett</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Santin</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Roman</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Hauer-Jensen</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Local administration of interleukin-11 ameliorates intestinal radiation injury in rats</article-title>
                  <source>Cancer Res</source>
                  <year>2007</year>
                  <volume>67</volume>
                  <issue>19</issue>
                  <fpage>9501</fpage>
                  <lpage>9506</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472</pub-id>
                  <?supplied-pmid 17909060?>
                  <pub-id pub-id-type="pmid">17909060</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gong</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Zhuo</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Topical application of honey in the management of chemo/radiotherapy-induced oral mucositis: a systematic review and network meta-analysis</article-title>
                  <source>Int J Nurs Stud</source>
                  <year>2019</year>
                  <volume>89</volume>
                  <fpage>80</fpage>
                  <lpage>87</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijnurstu</pub-id>
                  <?supplied-pmid 30352321?>
                  <pub-id pub-id-type="pmid">30352321</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yarom</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hovan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bossi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ariyawardana</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Gobbo</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines-part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents</article-title>
                  <source>Support Care Cancer</source>
                  <year>2020</year>
                  <volume>28</volume>
                  <issue>5</issue>
                  <fpage>2457</fpage>
                  <lpage>2472</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-019-05256-4</pub-id>
                  <?supplied-pmid 32056010?>
                  <pub-id pub-id-type="pmid">32056010</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dodd</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>MacPhail</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Miaskowski</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized clinical trial of granulocyte macrophage colony stimulating factor mouthwash for oral mucositis in head and neck cancer</article-title>
                  <source>Eur J Oncol Nurs</source>
                  <year>2022</year>
                  <volume>56</volume>
                  <fpage>102093</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejon.2022.102093</pub-id>
                  <?supplied-pmid 35026498?>
                  <pub-id pub-id-type="pmid">35026498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Logan</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Al-Azri</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Bossi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Stringer</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Joy</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Soga</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines</article-title>
                  <source>Support Care Cancer</source>
                  <year>2020</year>
                  <volume>28</volume>
                  <issue>5</issue>
                  <fpage>2485</fpage>
                  <lpage>2498</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-019-05170-9</pub-id>
                  <?supplied-pmid 32080767?>
                  <pub-id pub-id-type="pmid">32080767</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ya-Ting</surname>
                      <given-names>Yu</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>J-L</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>X-R</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Z-Z</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>X-H</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of 9 oral care solutions on the prevention of oral mucositis: a network meta-analysis of randomized controlled trials</article-title>
                  <source>Medicine</source>
                  <year>2020</year>
                  <volume>99</volume>
                  <issue>16</issue>
                  <fpage>e19661</fpage>
                  <pub-id pub-id-type="doi">10.1097/MD.0000000000019661</pub-id>
                  <pub-id pub-id-type="pmid">32311938</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nicolatou-Galitis</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Bossi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Orlandi</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bensadoun</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis</article-title>
                  <source>Support Care Cancer</source>
                  <year>2021</year>
                  <volume>29</volume>
                  <issue>10</issue>
                  <fpage>5701</fpage>
                  <lpage>5709</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-021-06048-5</pub-id>
                  <?supplied-pmid 33649918?>
                  <pub-id pub-id-type="pmid">33649918</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Villa</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sonis</surname>
                      <given-names>ST</given-names>
                    </name>
                  </person-group>
                  <article-title>Mucositis: pathobiology and management</article-title>
                  <source>Curr Opin Oncol</source>
                  <year>2015</year>
                  <volume>27</volume>
                  <issue>3</issue>
                  <fpage>159</fpage>
                  <lpage>164</lpage>
                  <pub-id pub-id-type="doi">10.1097/CCO.0000000000000180</pub-id>
                  <?supplied-pmid 25774860?>
                  <pub-id pub-id-type="pmid">25774860</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
